Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice-Reference-Cited by-同舟云学术

Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice

Published:2022-12-28 Issue:3 Volume:64 Page:679-690
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Montoro Maria Julia¹^ORCID,Pomares Helena²,Coll Rosa³,Bernal del Castillo Teresa⁴^ORCID,Tormo Mar⁵^ORCID,Jiménez Ana⁶,Brunet Salut⁷,Casaño Javier⁸,Oiartzabal Itziar⁹,Díez-Campelo María¹⁰^ORCID,Ramos Fernando¹¹^ORCID,Romero Rafael¹²,Salido-Fiérrez Eduardo¹³,Pedro Carmen¹⁴,Bargay Joan¹⁵,Muñoz-Novas Carolina¹⁶,López Rocío¹⁷,Rafel Montserrat¹⁷,Valcárcel David¹^ORCID,

Affiliation:

1. Department of Hematology, Hospital Universitari Vall d´Hebron, Barcelona, Spain

2. ICO-Hospital Duran i Reynals, IDIBELL, L'Hospitalet de Llobregat, Spain

3. ICO-Hospital Universitari Doctor Josep Trueta, Girona, Spain

4. Hospital Universitario Central de Asturias, Oviedo, Spain

5. Hospital Clínico Universitario de Valencia e Instituto de Investigación INCLIVA, Valencia, Spain

6. Hospital Universitario Ramón y Cajal, Madrid, Spain

7. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

8. Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain

9. Hospital Universitario Araba, Vitoria-Gasteiz, Spain

10. Hospital Clínico Universitario de Salamanca, Salamanca, Spain

11. Hospital Universitario de León, León, Spain

12. Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Spain

13. Hospital Clínico Universitario Virgen de la Arrixaca-IMIB, Murcia, Spain

14. Hospital del Mar, Barcelona, Spain

15. Hospital Son Llàtzer, Palma de Mallorca, Spain

16. Hospital Universitario Infanta Leonor, Madrid, Spain

17. Celgene S.L.U., a Bristol-Myers Squibb Company, Madrid, Spain

Funder

Celgene S.L.U., a Bristol-Myers Squibb Company

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2022.2154604

Reference29 articles.

1. ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter

2. An update on treatment of higher risk myelodysplastic syndromes

3. Evolving classifications of the myelodysplastic syndromes

4. Grupo Español de Síndromes Mielodisplásicos (GESMD). Guías españolas para el diagnóstico y tratamiento de los SMD y la LMMC. 2020. http://www.gesmd.es/wp-content/uploads/2021/10/GuiaSMDLMMC2020.pdf

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Physicist and the Philosopher;2015-12-31